Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-4 Registration of securities (foreign)
- 3.1 EX-3.1
- 4.1 EX-4.1
- 4.2 EX-4.2
- 5.1 EX-5.1
- 8.1 EX-8.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.6.1 EX-10.6.1
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.20.1 EX-10.20.1
- 10.20.2 EX-10.20.2
- 10.20.3 EX-10.20.3
- 10.21 EX-10.21
- 10.21.1 EX-10.21.1
- 10.21.2 EX-10.21.2
- 10.22 EX-10.22
- 10.22.1 EX-10.22.1
- 10.22.2 EX-10.22.2
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 22.1 EX-22.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- 23.4 EX-23.4
- 99.1 EX-99.1
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
MREO similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated February 27, 2018, in the Registration Statement (FormF-4) and related Proxy Statement/Prospectus of Mereo BioPharma Group plc dated January 24, 2019.
/s/ Ernst & Young LLP |
Reading, United Kingdom January 24, 2019 |